肿瘤细胞治疗研究
英文原题：CAR-T cell therapies are coming after glioblastoma: An overview of early phase clinical trials and future perspectives.
CAR-T cell therapies are coming after glioblastoma: An overview of early phase clinical trials and future perspectives.
在 I 期试验 NCT02208362 中，抗 IL13Rα2 CAR-T 细胞在 65 例患者中进行了测试，疾病控制率为 50%，1 年生存率为 23%。
复发性胶质母细胞瘤尚无确立的标准治疗，患者生存期仍仅数月。近期临床证据提示，颅内递送CAR-T细胞具有可行性并显示抗肿瘤活性。在1期试验NCT02208362中，65例患者接受抗IL13Rα2 CAR-T细胞治疗，疾病控制率为50%，一年生存率为23%。两项多靶点CAR-T产品1期研究（NCT05168423及正在进行的NCT05660369）也显示生物学活性及早期但短暂的影像学应答。重要的是，颅内给药途径支持了深入转化研究：连续活检和脑脊液采样可评估CAR-T在肿瘤部位的功能并识别候选预测生物标志物。本综述比较这三项研究的设计和发现，综合总结关键经验，并展望提高CAR-T治疗实体瘤疗效的未来方向，重点聚焦胶质母细胞瘤。
Recurrent glioblastoma has no established standard of care, and survival remains limited to a few months. Recent clinical evidence suggests that the intracranial delivery of CAR-T cells is feasible and shows signs of antitumor activity. In the phase I trial NCT02208362, anti-IL13R 2 CAR-T cells were tested in 65 patients, yielding a 50% disease-control rate and 23% one-year survival. Two phase I studies of multi-target CAR-T products (NCT05168423, the ongoing NCT05660369) similarly showed bioactivity and early but transient radiological responses. Importantly, the intracranial route enabled rich translational research: serial biopsies and cerebrospinal fluid sampling allowed assessment of CAR-T cells function at the tumor site and the identification of candidate predictive biomarkers. In this review, we compare the designs and findings of these three studies and synthesize key lessons. We also outline future perspectives to improve the efficacy of CAR-T cell therapy in solid tumors, with a focus on glioblastoma.
MEMBER ACCOUNT
登录成功会直接打开下一页。
